SCHEMBL19689700

SCHEMBL19689700

CC(=O)c1ccc2c(c1)CCN2C(=O)OC(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 6/20 0.47
NOTUM Q6P988 5/20 0.47
ALDH1A1 P00352 3/20 0.46
HPGD P15428 2/20 0.46
KDM4E B2RXH2 1/20 0.46
RECQL P46063 1/20 0.46
MAPT P10636 2/20 0.46
HSD17B10 Q99714 1/20 0.46
CYP11B1 P15538 1/20 0.45
CYP11B2 P19099 1/20 0.45
NPC1 O15118 1/20 0.45
TP53 P04637 1/20 0.45
RAB9A P51151 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
DHODH Q02127 1/20 0.45
SRD5A1 P18405 1/20 0.45
ABHD6 Q9BV23 1/20 0.43
KCNJ1 P48048 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6629774 0.92 KDM4E (0.52) NOTUMALDH1A1KDM4EHSD17B10TP53
SCHEMBL30681278 0.90 GPR119 (0.45) GPR119NOTUMALDH1A1HPGDKDM4E
SCHEMBL30527088 0.89 DHODH (0.49) GPR119NOTUMALDH1A1HPGDKDM4E
SCHEMBL380505 0.89 DHODH (0.49) GPR119NOTUMALDH1A1HPGDKDM4E
SCHEMBL21724876 0.88 GPR119 (0.46) GPR119NOTUMALDH1A1HPGDKDM4E
SCHEMBL846218 0.87 HDAC1 (0.53) GPR119NOTUMALDH1A1HPGDKDM4E
SCHEMBL19689701 0.86 ALDH1A1 (0.51) GPR119ALDH1A1HPGDKDM4ERECQL
SCHEMBL6648532 0.85 KDM4E (0.58) NOTUMALDH1A1HPGDKDM4ERECQL
SCHEMBL1467023 0.84 GPR119 (0.43) GPR119NOTUMALDH1A1HPGDKDM4E
SCHEMBL8200750 0.83 NOTUM (0.64) GPR119NOTUMALDH1A1KDM4EDHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10759786-B2 1-tetrahydropyranylcarbonyl-2,3-dihydro-1H-indole compounds for treating cancer ELI LILLY AND COMPANY (US) 2020-09-01 US disclosed
EP-3468965-B1 1-TETRAHYDROPYRANYLCARBONYL-2,3-DIHYDRO-1H-INDOLE COMPOUNDS FOR TREATING CANCER LILLY CO ELI (US) 2020-04-29 EP disclosed
US-20190161477-A1 1-TETRAHYDROPYRANYLCARBONYL-2,3-DIHYDRO-IH-INDOLE COMPOUNDS FOR TREATING CANCER ELI LILLY AND COMPANY 2019-05-30 US disclosed
US-9872853-B2 2,3-dihydro-1H-indole compounds ELI LILLY AND COMPANY (US) 2018-01-23 US disclosed
US-20170354641-A1 2,3-DIHYDRO-1H-INDOLE COMPOUNDS ELI LILLY AND COMPANY 2017-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190161477-A1 1-TETRAHYDROPYRANYLCARBONYL-2,3-DIHYDRO-IH-INDOLE COMPOUNDS FOR TREATING CANCER MCL1, IDO1, GLI1 GPR119 120/4885NOTUM 3288/4885ALDH1A1 227/4885
US-10759786-B2 1-tetrahydropyranylcarbonyl-2,3-dihydro-1H-indole compounds for treating cancer MCL1, FOXM1, IDO1 GPR119 266/4885NOTUM 2801/4885ALDH1A1 234/4885
US-20170354641-A1 2,3-DIHYDRO-1H-INDOLE COMPOUNDS MCL1, IDO1, IDO2 GPR119 344/4885NOTUM 2844/4885ALDH1A1 148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.